The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Jascayd (nerandomilast), a twice‑daily oral preferential PDE4B inhibitor, for idiopathic pulmonary fibrosis (IPF), the first new FDA clearance in the indication in more than ten years. Phase III data published in the New England Journal of Medicine showed Jascayd slowed decline in lung function versus placebo over one year and registered a tolerability profile that analysts described as potentially preferable to older agents. Boehringer positions Jascayd alongside its established IPF franchise; analysts characterized the approval as a modest but meaningful advance that may prompt solid uptake given limited alternatives. Pricing and positioning relative to existing antifibrotics remain to be disclosed; the approval may also re‑energize competitors and new entrants pursuing IPF and other progressive fibrotic lung diseases.